Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

出版年份 2017 全文链接

标题

作者

关键词

出版物

Volume 9, Issue 6, Pages -

出版商

Impact Journals, LLC

发表日期

2018-01-01

DOI

10.18632/oncotarget.23795

联系作者

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now